147 related articles for article (PubMed ID: 23982212)
1. Combination of pharmacophore hypothesis, genetic function approximation model, and molecular docking to identify novel inhibitors of S6K1.
Zhang H; Xiang ML; Liang JY; Zeng T; Zhang XN; Zhang J; Yang SY
Mol Divers; 2013 Nov; 17(4):767-72. PubMed ID: 23982212
[TBL] [Abstract][Full Text] [Related]
2. Structure-based identification of potential inhibitors of ribosomal protein S6 kinase 1, targeting cancer therapy: a combined docking and molecular dynamics simulations approach.
Alam A; Khan MS; Mathur Y; Sulaimani MN; Farooqui N; Ahmad SF; Nadeem A; Yadav DK; Mohammad T
J Biomol Struct Dyn; 2024 Jul; 42(11):5758-5769. PubMed ID: 37365756
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel S6K1 inhibitors by an ensemble-based virtual screening method and molecular dynamics simulation.
Zhang H; Zhang HR; Zhang J; Hu ML; Ren L; Luo QQ; Qi HZ
J Mol Model; 2023 Mar; 29(4):102. PubMed ID: 36933164
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel S6K1 inhibitor, rosmarinic acid methyl ester, for treating cisplatin-resistant cervical cancer.
Nam KH; Yi SA; Nam G; Noh JS; Park JW; Lee MG; Park JH; Oh H; Lee J; Lee KR; Park HJ; Lee J; Han JW
BMC Cancer; 2019 Aug; 19(1):773. PubMed ID: 31387554
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.
Wan HL; Wang ZR; Li LL; Cheng C; Ji P; Liu JJ; Zhang H; Zou J; Yang SY
Chem Biol Drug Des; 2012 Sep; 80(3):366-73. PubMed ID: 22594639
[TBL] [Abstract][Full Text] [Related]
6. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
Di-wu L; Li LL; Wang WJ; Xie HZ; Yang J; Zhang CH; Huang Q; Zhong L; Feng S; Yang SY
J Mol Graph Model; 2012 Jun; 36():42-7. PubMed ID: 22516037
[TBL] [Abstract][Full Text] [Related]
7. Development of organometallic S6K1 inhibitors.
Qin J; Rajaratnam R; Feng L; Salami J; Barber-Rotenberg JS; Domsic J; Reyes-Uribe P; Liu H; Dang W; Berger SL; Villanueva J; Meggers E; Marmorstein R
J Med Chem; 2015 Jan; 58(1):305-14. PubMed ID: 25356520
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Toxoplasma gondii virulence factor ROP18 competitive inhibitors by virtual screening.
Yin K; Zhao G; Xu C; Qiu X; Wen B; Sun H; Liu G; Liu Y; Zhao Q; Wei Q; Huang B; Yan G; Cao J
Parasit Vectors; 2019 Mar; 12(1):98. PubMed ID: 30867024
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel focal adhesion kinase inhibitors using a hybrid protocol of virtual screening approach based on multicomplex-based pharmacophore and molecular docking.
Wu F; Xu T; He G; Ouyang L; Han B; Peng C; Song X; Xiang M
Int J Mol Sci; 2012 Nov; 13(12):15668-78. PubMed ID: 23443087
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
11. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of the S6K1 kinase domain in complexes with inhibitors.
Niwa H; Mikuni J; Sasaki S; Tomabechi Y; Honda K; Ikeda M; Ohsawa N; Wakiyama M; Handa N; Shirouzu M; Honma T; Tanaka A; Yokoyama S
J Struct Funct Genomics; 2014 Sep; 15(3):153-64. PubMed ID: 25078151
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.
Xie HZ; Lan H; Pan YL; Zou J; Wang ZR; Li LL; Huang Q; Zhang H; Yang SY
Chem Biol Drug Des; 2013 Feb; 81(2):175-84. PubMed ID: 23107363
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel FAK and S6K1 dual inhibitors from natural compounds via ADMET screening and molecular docking.
Thiyagarajan V; Lin SH; Chang YC; Weng CF
Biomed Pharmacother; 2016 May; 80():52-62. PubMed ID: 27133039
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of ribosomal protein S6 kinase 1 at Thr421/Ser424 and dephosphorylation at Thr389 regulates SP600125-induced polyploidization of megakaryocytic cell lines.
Li CL; Yang JG; Lin D; Zhao YS; Liu S; Xing SN; Zhao S; Chen CQ; Jiang ZM; Pu FF; Cao JP; Ma DC
PLoS One; 2014; 9(12):e114389. PubMed ID: 25486532
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.
Xie HZ; Li LL; Ren JX; Zou J; Yang L; Wei YQ; Yang SY
Bioorg Med Chem Lett; 2009 Apr; 19(7):1944-9. PubMed ID: 19254842
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel GSK-3β Inhibitors Using Pharmacophore and Virtual Screening Studies.
Balakrishnan N; Raj JS; Kandakatla N
Interdiscip Sci; 2016 Sep; 8(3):303-11. PubMed ID: 26298578
[TBL] [Abstract][Full Text] [Related]
18. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1).
Pearce LR; Alton GR; Richter DT; Kath JC; Lingardo L; Chapman J; Hwang C; Alessi DR
Biochem J; 2010 Oct; 431(2):245-55. PubMed ID: 20704563
[TBL] [Abstract][Full Text] [Related]
19. Identification of Novel Src Inhibitors: Pharmacophore-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations.
Zhang Y; Zhang TJ; Tu S; Zhang ZH; Meng FH
Molecules; 2020 Sep; 25(18):. PubMed ID: 32911607
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening.
Yuan K; Min W; Wang X; Li J; Kuang W; Zhang F; Xie S; Yang P
Future Med Chem; 2020 Jun; 12(12):1121-1136. PubMed ID: 32400188
[No Abstract] [Full Text] [Related]
[Next] [New Search]
